Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Atlantis grabs $9.8m in series D:

This article was originally published in Clinica

Executive Summary

Cambridge, Massachusetts-based dental implant developer Atlantis Components has raised $9.8m in a series D financing. The round included the participation of new investor Signet Healthcare Partners as well as its existing shareholders, which include, among others ABV, CID Equity Capital and Ironwood Equity Fund. Proceeds from the financing will go towards expanding Atlantis' market presence. The company produces patient-specific dental implants using 3D digital imaging and integrated manufacturing methods.

You may also be interested in...



US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market

Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel